{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:06:19Z","timestamp":1791421579118,"version":"4.3.3"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19 is a pan B-cell surface receptor expressed from pro\u2013B-cell development until its down-regulation during terminal differentiation into plasma cells. CD19 represents an attractive immunotherapy target for cancers of lymphoid origin due to its high expression levels on the vast majority of non\u2013Hodgkin's lymphomas and some leukemias. A humanized anti-CD19 antibody with an engineered Fc domain (XmAb5574) was generated to increase binding to Fc\u03b3 receptors on immune cells and thus increase Fc-mediated effector functions. In vitro, XmAb5574 enhanced antibody-dependent cell-mediated cytotoxicity 100-fold to 1,000-fold relative to an anti-CD19 IgG1 analogue against a broad range of B-lymphoma and leukemia cell lines. Furthermore, XmAb5574 conferred antibody-dependent cell-mediated cytotoxicity against patient-derived acute lymphoblastic leukemia and mantle cell lymphoma cells, whereas the IgG1 analogue was inactive. XmAb5574 also increased antibody-dependent cellular phagocytosis and apoptosis. In vivo, XmAb5574 significantly inhibited lymphoma growth in prophylactic and established mouse xenograft models, and showed more potent antitumor activity than its IgG1 analogue. Comparisons with a variant incapable of Fc\u03b3 receptor binding showed that engagement of these receptors is critical for optimal antitumor efficacy. These results suggest that XmAb5574 exhibits potent tumor cytotoxicity via direct and indirect effector functions and thus warrants clinical evaluation as an immunotherapeutic for CD19+ hematologic malignancies. [Cancer Res 2008;68(19):8049\u201357]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2268","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:53:23Z","timestamp":1222822403000},"page":"8049-8057","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":249,"title":["Potent\n                    <i>In vitro<\/i>\n                    and\n                    <i>In vivo<\/i>\n                    Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia"],"prefix":"10.1158","volume":"68","author":[{"given":"Holly M.","family":"Horton","sequence":"first","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bernett","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Pong","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[{"name":"2Section of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sher","family":"Karki","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Y.","family":"Chu","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Richards","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Vostiar","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Joyce","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Repp","sequence":"additional","affiliation":[{"name":"2Section of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Desjarlais","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene A.","family":"Zhukovsky","sequence":"additional","affiliation":[{"name":"1Xencor, Inc., Monrovia, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"2022061700263240200_B1","doi-asserted-by":"crossref","unstructured":"Tedder TF, Inaoki M, Sato S. The CD19-21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity\u20081997; 6: 107\u201318.","DOI":"10.1016\/S1074-7613(00)80418-5"},{"key":"2022061700263240200_B2","doi-asserted-by":"crossref","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood\u20081984; 63: 1424\u201333.","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"2022061700263240200_B3","doi-asserted-by":"crossref","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol\u20081998; 51: 364\u20139.","DOI":"10.1136\/jcp.51.5.364"},{"key":"2022061700263240200_B4","doi-asserted-by":"crossref","unstructured":"Harris NL, Stein H, Coupland SE, et al. New approaches to lymphoma diagnosis. Hematology Am Soc Hematol Educ Program 2001:194\u2013220.","DOI":"10.1182\/asheducation-2001.1.194"},{"key":"2022061700263240200_B5","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res\u20081999; 5: 611\u20135."},{"key":"2022061700263240200_B6","doi-asserted-by":"crossref","unstructured":"Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol\u20082002; 119: 412\u20136.","DOI":"10.1046\/j.1365-2141.2002.03843.x"},{"key":"2022061700263240200_B7","doi-asserted-by":"crossref","unstructured":"Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology Am Soc Hematol Educ Program\u20082007; 2007: 233\u201342.","DOI":"10.1182\/asheducation-2007.1.233"},{"key":"2022061700263240200_B8","doi-asserted-by":"crossref","unstructured":"Vlasveld LT, Hekman A, Vyth-Dreese FA, et al. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother\u20081995; 40: 37\u201347.","DOI":"10.1007\/BF01517234"},{"key":"2022061700263240200_B9","doi-asserted-by":"crossref","unstructured":"Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A\u20082005; 102: 15178\u201383.","DOI":"10.1073\/pnas.0505539102"},{"key":"2022061700263240200_B10","doi-asserted-by":"crossref","unstructured":"Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol\u20081993; 11: 726\u201337.","DOI":"10.1200\/JCO.1993.11.4.726"},{"key":"2022061700263240200_B11","doi-asserted-by":"crossref","unstructured":"Rowland AJ, Pietersz GA, McKenzie IF. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol Immunother\u20081993; 37: 195\u2013202.","DOI":"10.1007\/BF01525435"},{"key":"2022061700263240200_B12","unstructured":"Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res\u20082002; 62: 7190\u20134."},{"key":"2022061700263240200_B13","doi-asserted-by":"crossref","unstructured":"Molhoj M, Crommer S, Brischwein K, et al. CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol\u20082007; 44: 1935\u201343.","DOI":"10.1016\/j.molimm.2006.09.032"},{"key":"2022061700263240200_B14","doi-asserted-by":"crossref","unstructured":"Bruenke J, Barbin K, Kunert S, et al. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgRIII (CD16). Br J Haematol\u20082005; 130: 218\u201328.","DOI":"10.1111\/j.1365-2141.2005.05414.x"},{"key":"2022061700263240200_B15","doi-asserted-by":"crossref","unstructured":"Hekman A, Honselaar A, Vuist WM, et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother\u20081991; 32: 364\u201372.","DOI":"10.1007\/BF01741331"},{"key":"2022061700263240200_B16","doi-asserted-by":"crossref","unstructured":"Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody. Science\u20082008; 321: 974\u20137.","DOI":"10.1126\/science.1158545"},{"key":"2022061700263240200_B17","doi-asserted-by":"crossref","unstructured":"Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today\u20082007; 12: 898\u2013910.","DOI":"10.1016\/j.drudis.2007.08.009"},{"key":"2022061700263240200_B18","doi-asserted-by":"crossref","unstructured":"Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood\u20082006; 108: 2648\u201354.","DOI":"10.1182\/blood-2006-04-020057"},{"key":"2022061700263240200_B19","doi-asserted-by":"crossref","unstructured":"Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A\u20082006; 103: 4005\u201310.","DOI":"10.1073\/pnas.0508123103"},{"key":"2022061700263240200_B20","doi-asserted-by":"crossref","unstructured":"Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem\u20082001; 276: 6591\u2013604.","DOI":"10.1074\/jbc.M009483200"},{"key":"2022061700263240200_B21","doi-asserted-by":"crossref","unstructured":"Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcg receptors. Cancer Res\u20082007; 67: 8882\u201390.","DOI":"10.1158\/0008-5472.CAN-07-0696"},{"key":"2022061700263240200_B22","doi-asserted-by":"crossref","unstructured":"Tedder TF, Baras A, Xiu Y. Fcg receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol\u20082006; 28: 351\u201364.","DOI":"10.1007\/s00281-006-0057-9"},{"key":"2022061700263240200_B23","doi-asserted-by":"crossref","unstructured":"Meeker TC, Miller RA, Link MP, Bindl J, Warnke R, Levy R. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma\u20081984; 3: 305\u201320.","DOI":"10.1089\/hyb.1984.3.305"},{"key":"2022061700263240200_B24","doi-asserted-by":"crossref","unstructured":"Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol\u20082007; 44: 1986\u201398.","DOI":"10.1016\/j.molimm.2006.09.029"},{"key":"2022061700263240200_B25","doi-asserted-by":"crossref","unstructured":"Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol\u20082007; 368: 652\u201365.","DOI":"10.1016\/j.jmb.2007.02.024"},{"key":"2022061700263240200_B26","doi-asserted-by":"crossref","unstructured":"Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol\u20081973; 22: 3099\u2013108.","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"2022061700263240200_B27","doi-asserted-by":"crossref","unstructured":"Peipp M, Schneider-Merck T, Dechant M, et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol\u20082008; 180: 4338\u201345.","DOI":"10.4049\/jimmunol.180.6.4338"},{"key":"2022061700263240200_B28","doi-asserted-by":"crossref","unstructured":"Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther\u20082008; 7: 2517\u201327.","DOI":"10.1158\/1535-7163.MCT-08-0201"},{"key":"2022061700263240200_B29","doi-asserted-by":"crossref","unstructured":"Chatenoud L, Bach JF. Antigenic modulation\u2014a major mechanism of antibody action. Immunol Today\u20081984; 5: 20\u20135.","DOI":"10.1016\/0167-5699(84)90061-6"},{"key":"2022061700263240200_B30","unstructured":"Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res\u20081989; 49: 4906\u201312."},{"key":"2022061700263240200_B31","doi-asserted-by":"crossref","unstructured":"Ingle GS, Chan P, Elliott JM, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol\u20082008; 140: 46\u201358.","DOI":"10.1111\/j.1365-2141.2007.06883.x"},{"key":"2022061700263240200_B32","doi-asserted-by":"crossref","unstructured":"Barbin K, Stieglmaier J, Saul D, et al. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. J Immunother (1997)\u20082006; 29: 122\u201333.","DOI":"10.1097\/01.cji.0000175684.28615.7b"},{"key":"2022061700263240200_B33","doi-asserted-by":"crossref","unstructured":"Benoit NE, Wade WF. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Immunopharmacology\u20081996; 35: 129\u201339.","DOI":"10.1016\/S0162-3109(96)00138-5"},{"key":"2022061700263240200_B34","doi-asserted-by":"crossref","unstructured":"Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19\/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol\u20081992; 149: 2841\u201350.","DOI":"10.4049\/jimmunol.149.9.2841"},{"key":"2022061700263240200_B35","doi-asserted-by":"crossref","unstructured":"Xu Y, Szalai AJ, Zhou T, et al. FcgRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol\u20082003; 171: 562\u20138.","DOI":"10.4049\/jimmunol.171.2.562"},{"key":"2022061700263240200_B36","doi-asserted-by":"crossref","unstructured":"Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol\u20082006; 33: S2\u201314.","DOI":"10.1053\/j.seminoncol.2006.01.024"},{"key":"2022061700263240200_B37","doi-asserted-by":"crossref","unstructured":"Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene\u20082007; 26: 3629\u201336.","DOI":"10.1038\/sj.onc.1210365"},{"key":"2022061700263240200_B38","doi-asserted-by":"crossref","unstructured":"Nijmeijer B, van Schie MLJ, Willemze R, Falkenburg JHF. Rituximab and alemtuzumab in combination, but not alone, induce complete remissions in a preclinical animal model of primary human ALL: rationale for combination treatment [abstract]. Blood\u20082007; 110: 2833.","DOI":"10.1182\/blood.V110.11.2833.2833"},{"key":"2022061700263240200_B39","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia-long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma\u20082003; 44: 1719\u201325.","DOI":"10.1080\/1042819031000116706"},{"key":"2022061700263240200_B40","doi-asserted-by":"crossref","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med\u20082000; 6: 443\u20136.","DOI":"10.1038\/74704"},{"key":"2022061700263240200_B41","doi-asserted-by":"crossref","unstructured":"Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood\u20082002; 99: 754\u20138.","DOI":"10.1182\/blood.V99.3.754"},{"key":"2022061700263240200_B42","doi-asserted-by":"crossref","unstructured":"Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol\u20082003; 21: 3940\u20137.","DOI":"10.1200\/JCO.2003.05.013"},{"key":"2022061700263240200_B43","doi-asserted-by":"crossref","unstructured":"Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer. J Clin Oncol\u20082008; 26: 1789\u201396.","DOI":"10.1200\/JCO.2007.14.8957"},{"key":"2022061700263240200_B44","doi-asserted-by":"crossref","unstructured":"Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science\u20082005; 310: 1510\u20132.","DOI":"10.1126\/science.1118948"},{"key":"2022061700263240200_B45","doi-asserted-by":"crossref","unstructured":"Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol\u20082005; 23: 474\u201381.","DOI":"10.1200\/JCO.2005.06.059"},{"key":"2022061700263240200_B46","doi-asserted-by":"crossref","unstructured":"Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcg receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med\u20082006; 203: 743\u201353.","DOI":"10.1084\/jem.20052283"},{"key":"2022061700263240200_B47","doi-asserted-by":"crossref","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med\u20082004; 199: 1659\u201369.","DOI":"10.1084\/jem.20040119"},{"key":"2022061700263240200_B48","doi-asserted-by":"crossref","unstructured":"McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood\u20082007; 109: 1185\u201392.","DOI":"10.1182\/blood-2006-07-034017"},{"key":"2022061700263240200_B49","doi-asserted-by":"crossref","unstructured":"Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AE, Slaper-Cortenbach IC. Fc g receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood\u20081994; 83: 1632\u20139.","DOI":"10.1182\/blood.V83.6.1632.bloodjournal8361632"},{"key":"2022061700263240200_B50","doi-asserted-by":"crossref","unstructured":"Cherukuri A, Cheng PC, Pierce SK. The role of the CD19\/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol\u20082001; 167: 163\u201372.","DOI":"10.4049\/jimmunol.167.1.163"},{"key":"2022061700263240200_B51","doi-asserted-by":"crossref","unstructured":"Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol\u20082003; 121: 458\u201361.","DOI":"10.1046\/j.1365-2141.2003.04305.x"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/8049\/2596616\/8049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/8049\/2596616\/8049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T01:52:19Z","timestamp":1684547539000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/19\/8049\/541320\/Potent-In-vitro-and-In-vivo-Activity-of-an-Fc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2008,9,30]]},"published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2268","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22375889","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375880.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375886.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498011.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375883.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375889.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375880","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375886","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375883","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}